Study #2022-0432
A phase 3 randomized, placebo-controlled trial evaluating Memantine (IND# 149832) for neurocognitive protection in children undergoing cranial radiotherapy as part of treatment for primary central nervous system tumors.
MD Anderson Study Status
Enrolling
Treatment Agent
Memantine Hydrochloride, Placebo Administration
Description
This phase III trial compares memantine to placebo in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary central nervous system tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Central Nervous System Carcinoma
Study phase:
Phase III
Physician name:
Najat Daw Bitar
Department:
Pediatrics
For general questions about clinical trials:
1-888-912-0153
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.